Literature DB >> 29713056

Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways.

Xiaofan Guo1, Wei Qiu1, Qinglin Liu2, Mingyu Qian1, Shaobo Wang1, Zongpu Zhang1, Xiao Gao1, Zihang Chen1, Hao Xue3,4, Gang Li5,6.   

Abstract

While immunosuppressive environments mediated by myeloid-derived suppressor cells (MDSCs) have been well documented in glioma patients, the mechanisms of MDSC development and activation have not been clearly defined. Here, we elucidated a role for glioma-derived exosomes (GDEs) in potentiating an MDSC pathway. We isolated normoxia-stimulated and hypoxia-stimulated GDEs and studied their MDSC induction abilities in vivo and in vitro. Analyses of spleen and bone marrow MDSC proportions (flow cytometry) and reactive oxygen species (ROS), arginase activity, nitric oxide (NO), T-cell proliferation and immunosuppressive cytokine (IL-10 and TGF-β, ELISA) levels were used to assess MDSC expansion and functional capacity. We also performed microRNA (miRNA) sequencing analysis of two types of GDEs to find miRNAs that potentially mediate the development and activation of MDSCs. GDE miRNA intracellular signaling in MDSCs was also studied. Hypoxia promoted the secretion of GDEs, and mouse MDSCs could uptake GDEs. Hypoxia-stimulated GDEs had a stronger ability to induce MDSCs than N-GDEs. The hypoxia-inducible expression of miR-10a and miR-21 in GDEs mediated GDE-induced MDSC expansion and activation by targeting RAR-related orphan receptor alpha (RORA) and phosphatase and tensin homolog (PTEN). Mice inoculated with miR-10a or miR-21 knockout glioma cells generated fewer MDSCs than those inoculated with normal glioma cells. These data elucidated a mechanism by which glioma cells influence the differentiation and activation of MDSCs via exosomes and demonstrated how local glioma hypoxia affects the entirety of tumor immune environments.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29713056     DOI: 10.1038/s41388-018-0261-9

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  49 in total

1.  The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response.

Authors:  P Delerive; D Monté; G Dubois; F Trottein; J Fruchart-Najib; J Mariani; J C Fruchart; B Staels
Journal:  EMBO Rep       Date:  2001-01       Impact factor: 8.807

2.  Glioma-derived extracellular vesicles selectively suppress immune responses.

Authors:  Justin E Hellwinkel; Jasmina S Redzic; Tessa A Harland; Dicle Gunaydin; Thomas J Anchordoquy; Michael W Graner
Journal:  Neuro Oncol       Date:  2015-09-18       Impact factor: 12.300

3.  Induction of myeloid-derived suppressor cells by tumor exosomes.

Authors:  Xiaoyu Xiang; Anton Poliakov; Cunren Liu; Yuelong Liu; Zhong-bin Deng; Jianhua Wang; Ziqiang Cheng; Spandan V Shah; Gui-Jun Wang; Liming Zhang; William E Grizzle; Jim Mobley; Huang-Ge Zhang
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

4.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

5.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.

Authors:  Hadi Valadi; Karin Ekström; Apostolos Bossios; Margareta Sjöstrand; James J Lee; Jan O Lötvall
Journal:  Nat Cell Biol       Date:  2007-05-07       Impact factor: 28.824

6.  Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion.

Authors:  Balint Otvos; Daniel J Silver; Erin E Mulkearns-Hubert; Alvaro G Alvarado; Soumya M Turaga; Mia D Sorensen; Patricia Rayman; William A Flavahan; James S Hale; Kevin Stoltz; Maksim Sinyuk; Qiulian Wu; Awad Jarrar; Sung-Hak Kim; Paul L Fox; Ichiro Nakano; Jeremy N Rich; Richard M Ransohoff; James Finke; Bjarne W Kristensen; Michael A Vogelbaum; Justin D Lathia
Journal:  Stem Cells       Date:  2016-05-27       Impact factor: 6.277

7.  Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells.

Authors:  Hiroko Tadokoro; Tomohiro Umezu; Kazuma Ohyashiki; Toshihiko Hirano; Junko H Ohyashiki
Journal:  J Biol Chem       Date:  2013-10-16       Impact factor: 5.157

8.  Transcription factor RORα is critical for nuocyte development.

Authors:  See Heng Wong; Jennifer A Walker; Helen E Jolin; Lesley F Drynan; Emily Hams; Ana Camelo; Jillian L Barlow; Daniel R Neill; Veera Panova; Ute Koch; Freddy Radtke; Clare S Hardman; You Yi Hwang; Padraic G Fallon; Andrew N J McKenzie
Journal:  Nat Immunol       Date:  2012-01-22       Impact factor: 25.606

9.  Plasma exosome microRNAs are indicative of breast cancer.

Authors:  Bethany N Hannafon; Yvonne D Trigoso; Cameron L Calloway; Y Daniel Zhao; David H Lum; Alana L Welm; Zhizhuang J Zhao; Kenneth E Blick; William C Dooley; W Q Ding
Journal:  Breast Cancer Res       Date:  2016-09-08       Impact factor: 6.466

Review 10.  Extracellular vesicles: exosomes, microvesicles, and friends.

Authors:  Graça Raposo; Willem Stoorvogel
Journal:  J Cell Biol       Date:  2013-02-18       Impact factor: 10.539

View more
  87 in total

1.  The role of exosomes in tumor immunity.

Authors:  Huayu Yang; Lejia Sun; Yilei Mao
Journal:  Ann Transl Med       Date:  2018-12

Review 2.  The role of exosomal microRNAs in central nervous system diseases.

Authors:  Yifei Yu; Kun Hou; Tong Ji; Xishu Wang; Yining Liu; Yangyang Zheng; Jinying Xu; Yi Hou; Guangfan Chi
Journal:  Mol Cell Biochem       Date:  2021-01-29       Impact factor: 3.396

Review 3.  Exosomes in cancer development, metastasis, and immunity.

Authors:  Lin Zhang; Dihua Yu
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-04-30       Impact factor: 10.680

Review 4.  Strategies for the use of Extracellular Vesicles for the Delivery of Therapeutics.

Authors:  Susmita Sil; Raghubendra Singh Dagur; Ke Liao; Eric S Peeples; Guoku Hu; Palsamy Periyasamy; Shilpa Buch
Journal:  J Neuroimmune Pharmacol       Date:  2019-08-27       Impact factor: 4.147

5.  miR-21a in exosomes from Lewis lung carcinoma cells accelerates tumor growth through targeting PDCD4 to enhance expansion of myeloid-derived suppressor cells.

Authors:  Xingju Zhang; Fei Li; Ying Tang; Qinglan Ren; Bin Xiao; Ying Wan; Shan Jiang
Journal:  Oncogene       Date:  2020-08-27       Impact factor: 9.867

6.  Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer.

Authors:  Mengmeng Jiang; Wenwen Zhang; Rui Zhang; Pengpeng Liu; Yingnan Ye; Wenwen Yu; Xiaojing Guo; Jinpu Yu
Journal:  Oncogene       Date:  2020-05-12       Impact factor: 9.867

Review 7.  Exosomal noncoding RNAs in Glioma: biological functions and potential clinical applications.

Authors:  Jian Cheng; Jinli Meng; Lei Zhu; Yong Peng
Journal:  Mol Cancer       Date:  2020-03-25       Impact factor: 27.401

8.  Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-κB pathways.

Authors:  Mingyu Qian; Shaobo Wang; Xiaofan Guo; Jian Wang; Zongpu Zhang; Wei Qiu; Xiao Gao; Zihang Chen; Jianye Xu; Rongrong Zhao; Hao Xue; Gang Li
Journal:  Oncogene       Date:  2019-09-04       Impact factor: 9.867

9.  The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer.

Authors:  Malgorzata Czystowska-Kuzmicz; Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2020-09-08       Impact factor: 4.388

Review 10.  TGF-β links glycolysis and immunosuppression in glioblastoma.

Authors:  Lingli Gong; Li Ji; Daxing Xu; Jingjing Wang; Jian Zou
Journal:  Histol Histopathol       Date:  2021-07-29       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.